^
    1m
    Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Neoplastic Diseases. (PubMed, Acta Med Philipp)
    Through a comprehensive and systematic search of the best available evidence, the Neoplastic Diseases Task Force developed 20 recommendations on screening and risk factor assessment for 10 specific questions on neoplastic diseases. These recommendations serve as guidance on screening neoplastic diseases at the primary care level.
    Clinical guideline • Journal
    |
    AFP (Alpha-fetoprotein)
    1m
    LaserMucite: Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=97, Completed, Institut Cancerologie de l'Ouest | Unknown status --> Completed | Phase classification: P3 --> PN/A
    Trial completion • Phase classification
    1m
    A hypoxia-responsive migrasome-related lncRNA signature predicts prognosis and suggests the MSC-AS1/ITGA5 axis as a potential therapeutic target in head and neck squamous cell carcinoma. (PubMed, Funct Integr Genomics)
    Hypoxia upregulated the MSC-AS1/ITGA5 axis and increased VEGFA/PD-L1 expression, along with changes in the migrasome-related protein TSPAN4, suggesting a potential association with migrasome-related molecular features, which requires direct experimental validation. Collectively, our findings establish a novel MRL-based signature for prognostic prediction in HNSCC and highlight the hypoxia-responsive MSC-AS1/ITGA5 axis as a promising target for combinatorial therapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ITGA5 (Integrin Subunit Alpha 5)
    |
    PD-L1 expression
    1m
    Single Atom Ru Doped CuTi Nanozyme with Precisely Programmed Cascade Catalysis for Amplified Oral Cancer Therapy. (PubMed, ACS Nano)
    This approach achieved 84.7% tumor inhibition and prolonged survival in an orthotopic OSCC model. This work presents a chemical strategy that addresses fundamental CDT limitations through cascade catalysis with atomic-level tunability.
    Journal
    |
    CAT (Catalase)
    1m
    Trilaciclib Combined With Immunochemotherapy for R/M HNSCC (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial
    |
    Cosela (trilaciclib)
    1m
    Revealing biomechanical vulnerabilities in oral cancer cells using 3D coculture platform and low-frequency ultrasound. (PubMed, Mater Today Bio)
    Remarkably, a study using an elastomeric platform for coculture of patient-derived cancer and cancer-associated fibroblast (CAF) cells shows a significant reduction in CAFs' ability to infiltrate and compartmentalize the tumor core as well as encapsulate the tumor upon US treatment. Our findings suggest that an ultrasound-based strategy could be used to target the oral tumor microenvironment to augment existing cancer treatment and may open avenues for broader application in superficial malignancies.
    Journal
    |
    MIR21 (MicroRNA 21) • TPM2 (Tropomyosin 2)
    1m
    Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Stanford University | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    1m
    A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, West China Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Gilotrif (afatinib) • Tevimbra (tislelizumab-jsgr)
    1m
    PYX-201-101: A Study of PYX-201 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, Pyxis Oncology, Inc | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Apr 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    micvotabart pelidotin (PYX-201)
    1m
    A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=96 --> 210 | Trial completion date: Mar 2028 --> Mar 2029 | Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • SHR-A2102 • AiRuiLi (adebrelimab)
    1m
    CH CARE: Clonal Hematopoiesis Chemotherapy and Radiation Effects Study (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Dana-Farber Cancer Institute
    New trial
    1m
    Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) (clinicaltrials.gov)
    P2, N=36, Recruiting, Medical University of South Carolina | Initiation date: Jul 2026 --> Oct 2026
    Trial initiation date
    |
    NavDx®